Opioid Crisis (Commission)
Combating Drug Addiction and the

II. Method of Collection

III. Data

Title: Pilot Testing of Telephone Interviewing Approaches to Assess Community Response to New, Quieter Boom Experiences.
OMB Number: 2700–XXXX.
Type of review: New information collection.
Affected Public: Individuals.
Estimated Number of Respondents: 5,000.
Estimated Time per Response: 3 minutes.
Estimated Total Annual Burden Hours: 250.
Estimated Total Annual Cost to Respondents: $0.

IV. Request for Comments

Comments are invited on: (1) Whether the proposed collection of information is necessary for the proper performance of the functions of NASA, including whether the information collected has practical utility; (2) the accuracy of NASA’s estimate of the burden (including hours and cost) of the proposed collection of information; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) ways to minimize the burden of the collection of information on respondents, including automated collection techniques or the use of other forms of information technology.

Comments submitted in response to this notice will be summarized and included in the request for OMB approval of this information collection. They will also become a matter of public record.

Frances Teel,
NASA PRA Clearance Officer.

[FR Doc. 2017–12000 Filed 6–8–17; 8:45 am]
BILLING CODE 7510–13–P

OFFICE OF NATIONAL DRUG CONTROL POLICY

Notification of a Public Teleconference of the President’s Commission on Combating Drug Addiction and the Opioid Crisis (Commission)

AGENCY: Office of National Drug Control Policy (ONDCP).

ACTION: Notice of teleconference.

SUMMARY: ONDCP announces a meeting by teleconference of the President’s Commission on Combating Drug Addiction and the Opioid Crisis. The purpose of the meeting is to review a draft interim report that will be posted on ONDCP’s Commission Web site listed below before the teleconference.

DATES: The teleconference will be held on Monday June 26, 2017 at 4:00 p.m. (Eastern time).

ADDRESS: There will be no physical address. The public may call (866) 233–3841 (Access Code 423532) to listen. Please call five minutes before the start time. If you are part of an organization, please try to consolidate use to as few lines as possible.

FOR FURTHER INFORMATION CONTACT:
General information concerning the Commission and its meetings can be found on ONDCP’s Web site at https://www.whitehouse.gov/ondcp/presidents-commission. Any member of the public wishing to obtain information about the Commission or its meetings that is not already on ONDCP’s Web site or who wishes to submit written comments for the Commission’s consideration may contact Michael Passante, Designated Federal Officer (DFO) via email at commission@ondcp.eop.gov or telephone at (202) 395–6709. Please note that ONDCP may post such written comments publicly on our Web site, including names and contact information that are submitted. There will not be oral comments from the public on the teleconference. Requests to accommodate disabilities should also be sent to that email address, preferably at least 10 days prior to the meeting to allow time for processing.

SUPPLEMENTARY INFORMATION: The Commission was established in accordance with E.O. 13784 of March 29, 2017, the Commission’s charter, and the provisions of the Federal Advisory Committee Act (FACA), as amended, 5 U.S.C. App. 2, to obtain advice and recommendations for the President regarding drug issues. The Executive Order, charter, and information on the Members of the Commission are available on ONDCP’s Web site. The Commission will function solely as an advisory body and will make recommendations regarding policies and practices for combating drug addiction with particular focus on the current opioid crisis in the United States. The Commission’s final report is due October 1, 2017 unless there is an extension. Per E.O. 13784, the Commission shall:
a. Identify and describe the existing Federal funding used to combat drug addiction and the opioid crisis;
b. assess the availability and accessibility of drug addiction treatment services and overdose reversal throughout the country and identify areas that are underserved;
c. identify and report on best practices for addiction prevention, including healthcare provider education and evaluation of prescription practices, collaboration between State and Federal officials, and the use and effectiveness of State prescription drug monitoring programs;
d. review the literature evaluating the effectiveness of educational messages for youth and adults with respect to prescription and illicit opioids;
e. identify and evaluate existing Federal programs to prevent and treat drug addiction for their scope and effectiveness, and make recommendations for improving these programs; and;
f. make recommendations to the President for improving the Federal response to drug addiction and the opioid crisis.

Dated: June 6, 2017.

Michael Passante,
Acting General Counsel, Designated Federal Officer.

[FR Doc. 2017–12023 Filed 6–8–17; 8:45 am]
BILLING CODE 3280–F5–P

NATIONAL SCIENCE FOUNDATION

Sunshine Act Meeting; National Science Board

The National Science Board’s Committee on Awards and Facilities (A&F), pursuant to NSF regulations (45 CFR part 614), the National Science Foundation Act, as amended (42 U.S.C. 1862n–5), and the Government in the Sunshine Act (5 U.S.C. 552b), hereby gives notice of the scheduling of a teleconference for the transaction of National Science Board business, as follows:

DATES AND TIME: Friday, June 16, 2017 from 11:00 a.m.–12:00 p.m. EDT.

SUBJECT MATTER: Committee Chair’s opening remarks; discussion of Information-Action Item Sequence; the Lead Reviewer Guide; the Portfolio Level Information in Facility Portal; and Committee Chair’s closing remarks.

STATUS: Open.

LOCATION: This meeting will be held by teleconference at the National Science Foundation, 4201 Wilson Blvd., Arlington, VA 22230. An audio link will be available for the public. Members of the public must contact the Board Office to request the public audio link by sending an email to nationalscienceboard@nsf.gov at least 24 hours prior to the teleconference.
FOR ADDITIONAL INFORMATION CONTACT:
Suzanne H. Plimpton, Reports Clearance Officer, National Science Foundation, 4201 Wilson Boulevard, Suite 1265, Arlington, Virginia 22230; telephone (703) 292–7556; or send email to splimpto@nsf.gov. Individuals who use a telecommunications device for the deaf (TDD) may call the Federal Information Relay Service (FIRS) at 1–800–877–8339, which is accessible 24 hours a day, 7 days a week, 365 days a year (including Federal holidays).
NSF may not conduct or sponsor a collection of information unless the collection of information displays a currently valid OMB control number and the agency informs potential persons who are to respond to the collection of information that such persons are not required to respond to the collection of information unless it displays a currently valid OMB control number.

SUPPLEMENTARY INFORMATION:
Title of Collection: Medical Clearance Process for Deployment to the Polar Regions (specified regions in the Arctic and all locations in the Antarctic under the auspices of the U.S. Antarctic Program).
OMB Control No.: 3145–0177.
Type of Request: Intent to seek approval to renew an information collection for three years.

Abstract
Proposed Project: Presidential Memorandum No. 6646 (February 5, 1982) (available from the National Science Foundation, Office of Polar Programs, Suite 755, 4201 Wilson Boulevard, Arlington, VA 22230) sets forth the National Science Foundation’s overall management responsibilities for the entire United States national program in Antarctica. Section 107(a) of Public Law 98–373 (July 31, 1984; amended as Public Law 101–609–November 16, 1990) (available from the National Science Foundation, Office of Polar Programs, Suite 755, 4201 Wilson Boulevard, Arlington, VA 22230) designates the National Science Foundation as the lead agency responsible for implementing Arctic research policy, and the Director of the National Science Foundation shall ensure that the requirements of section 108 are fulfilled.

NSF Form 1700, Medical Clearance Process for Deployment to the Polar Regions furnishes information to the NSF regarding the physical, dental, and mental health status for all individuals (except DoD-uniformed service personnel) who anticipate deploying to Antarctica under the auspices of the United States Antarctic Program or to certain regions of the Arctic sponsored by the NSF/CEO/Office of Polar Programs. The information is used to determine whether an individual is physically and mentally suited to endure the extreme hardships imposed by the Arctic and Antarctic continents, while also performing specific duties as specified by their employers.

Respondents: All non-DoD uniformed personnel planning to deploy to U.S. stations in the Antarctic or to specified regions of the Arctic that are sponsored by the National Science Foundation’s Office of Polar Programs.

The number of annual respondents: 3,500 to the Antarctic and 150 to the Arctic.

Estimated Total Annual Burden on Respondents: 36,500 hours.
Frequency of Responses: This form is submitted upon an individual’s first deployment to Antarctica (below 60° South) or to specified regions of the Arctic and annually thereafter for the duration of the individual’s deployments.

Dated: June 6, 2017.
Suzanne H. Plimpton,
Reports Clearance Officer.

NEIGHBORHOOD REINVESTMENT CORPORATION

Annual Board of Directors Meeting; Sunshine Act

TIME AND DATE: 3:00 p.m., Monday, June 19, 2017.
STATUS: Open (with the exception of Executive Sessions).

CONTACT PERSON: Jeffrey Bryson, EVP & General Counsel/Secretary, (202) 760–4101; jbryson@nw.org.

AGENDA:
I. CALL TO ORDER
II. Mission Moment
III. Executive Session: Report from CEO
IV. Executive Session: Internal Audit Report
V. Approval of Minutes
VI. Board Elections
VII. Grants to Capital Corporations
VIII. FY17 Budget Approval
IX. ETMS
X. CounselorMax
XI. Management Program Background and Updates
XII. Adjournment
The General Counsel of the Corporation has certified that in his...